Abnormal Cannabidiol (Abn-CBD) Cannabinoid Research

Abnormal Cannabidiol (Abn-CBD) Research Dashboard

10

Primary Studies

5

Related Studies

15

Total Studies

Clinical Studies

0

Clinical Meta-analyses

0

Double-blind human trials

0

Clinical human trials

Pre-Clinical Studies

3

Meta-analyses/Reviews

6

Animal studies

1

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 15 studies associated with Abnormal Cannabidiol (Abn-CBD).

Here is a small sampling of Abnormal Cannabidiol (Abn-CBD) studies by title:


Components of the Abnormal Cannabidiol (Abn-CBD) Research Dashboard

  • Top medical conditions associated with Abnormal Cannabidiol (Abn-CBD)
  • Proven effects in clinical trials for Abnormal Cannabidiol (Abn-CBD)
  • Receptors associated with Abnormal Cannabidiol (Abn-CBD)
  • Individual study details for Abnormal Cannabidiol (Abn-CBD)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Abnormal Cannabidiol (Abn-CBD)

Description of Abnormal Cannabidiol (Abn-CBD)

Abnormal CBD is a synthetic isomer of CBD and was discovered in 1974. A deeper scientific understanding of abnormal-CBD especially in the context of treating human illness remains largely wanting.

Other Names:

Abnormal Cannabidiol
Abnormal Cannabidiol (and numerous other supplier-based synonyms)

IUPAC Name: 4-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol

Molecular Formula: C21H30O2

Source–PubChem

Abnormal Cannabidiol (Abn-CBD) Properties and Effects

• Reduces intra-ocular pressure in test animals (A. Szczesniak et al., 2011)
• Non-psychoactive (M. Adams et al., 1977)
• Significant hypotension with minor bradycardia (M. Adams et al., 1977)

Abnormal Cannabidiol (Abn-CBD) Receptor Binding

Endocannabinoid system (ECS):
• Abn-CBD may be the ligand for GPR18 (D. McHugh et al., 2010)
• Abn-CBD is inactive at CB1 or CB2 (D. McHugh et al., 2010)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.